194 related articles for article (PubMed ID: 33527450)
21. Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma.
Li J; Xing X; Li D; Zhang B; Mutch DG; Hagemann IS; Wang T
Neoplasia; 2017 Feb; 19(2):100-111. PubMed ID: 28088687
[TBL] [Abstract][Full Text] [Related]
22. Establishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.
Chiba Y; Sato S; Itamochi H; Suga Y; Fukagawa T; Oumi N; Oishi T; Harada T; Sugai T; Sugiyama T
Hum Cell; 2017 Apr; 30(2):140-148. PubMed ID: 27889902
[TBL] [Abstract][Full Text] [Related]
23. Uterine adenosarcomas are mesenchymal neoplasms.
Piscuoglio S; Burke KA; Ng CK; Papanastasiou AD; Geyer FC; Macedo GS; Martelotto LG; de Bruijn I; De Filippo MR; Schultheis AM; Ioris RA; Levine DA; Soslow RA; Rubin BP; Reis-Filho JS; Weigelt B
J Pathol; 2016 Feb; 238(3):381-8. PubMed ID: 26592504
[TBL] [Abstract][Full Text] [Related]
24. PPP2R1A mutations are common in the serous type of endometrial cancer.
Nagendra DC; Burke J; Maxwell GL; Risinger JI
Mol Carcinog; 2012 Oct; 51(10):826-31. PubMed ID: 21882256
[TBL] [Abstract][Full Text] [Related]
25. Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case.
Watanabe M; Shimizu K; Kato H; Imai H; Nakano H; Sugawa M; Shiraishi T
Gynecol Oncol; 2001 Sep; 82(3):563-7. PubMed ID: 11520156
[TBL] [Abstract][Full Text] [Related]
26. Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework.
Lu X; Zhang L; Zhao H; Chen C; Wang Y; Liu S; Lin X; Wang Y; Zhang Q; Lu T; Yan F
Cancer Biol Ther; 2019; 20(2):227-235. PubMed ID: 30359167
[TBL] [Abstract][Full Text] [Related]
27. Esophageal carcinosarcoma with basaloid squamous carcinoma and rhabdomyosarcoma components with TP53 mutation.
Amatya VJ; Takeshima Y; Kaneko M; Inai K
Pathol Int; 2004 Oct; 54(10):803-9. PubMed ID: 15482572
[TBL] [Abstract][Full Text] [Related]
28. Two Components of Variant Profiles in Primary Vaginal Carcinosarcoma via Next-Generation Sequencing and a Literature Review.
Kotoku R; Yanazume S; Kuroda T; Kobayashi Y; Kitazono I; Akahane T; Tanimoto A; Kobayashi H
Int J Surg Pathol; 2022 May; 30(3):288-294. PubMed ID: 34463147
[TBL] [Abstract][Full Text] [Related]
29. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
[TBL] [Abstract][Full Text] [Related]
30. Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
Bashir S; Jiang G; Joshi A; Miller C; Matrai C; Yemelyanova A; Caputo TA; Holcomb KM; Ellenson LH; Gupta D
Int J Gynecol Cancer; 2014 Sep; 24(7):1262-7. PubMed ID: 25078343
[TBL] [Abstract][Full Text] [Related]
31. HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology.
Jenkins TM; Cantrell LA; Stoler MH; Mills AM
Am J Surg Pathol; 2022 Apr; 46(4):435-442. PubMed ID: 35125452
[TBL] [Abstract][Full Text] [Related]
32. Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma.
Inoue H; Hashimura M; Akiya M; Chiba R; Saegusa M
Mol Cancer; 2017 Feb; 16(1):37. PubMed ID: 28193280
[TBL] [Abstract][Full Text] [Related]
33. Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
Cuevas IC; Sahoo SS; Kumar A; Zhang H; Westcott J; Aguilar M; Cortez JD; Sullivan SA; Xing C; Hayes DN; Brekken RA; Bae-Jump VL; Castrillon DH
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25880-25890. PubMed ID: 31772025
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous basal cell carcinosarcomas: evidence of clonality and recurrent chromosomal losses.
Harms PW; Fullen DR; Patel RM; Chang D; Shalin SC; Ma L; Wood B; Beer TW; Siddiqui J; Carskadon S; Wang M; Palanisamy N; Fisher GJ; Andea A
Hum Pathol; 2015 May; 46(5):690-7. PubMed ID: 25704628
[TBL] [Abstract][Full Text] [Related]
35. RNA-seq Identification of RACGAP1 as a Metastatic Driver in Uterine Carcinosarcoma.
Mi S; Lin M; Brouwer-Visser J; Heim J; Smotkin D; Hebert T; Gunter MJ; Goldberg GL; Zheng D; Huang GS
Clin Cancer Res; 2016 Sep; 22(18):4676-86. PubMed ID: 27121792
[TBL] [Abstract][Full Text] [Related]
36. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
[TBL] [Abstract][Full Text] [Related]
37. Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?
Raspollini MR; Susini T; Amunni G; Paglierani M; Castiglione F; Garbini F; Carriero C; Scarselli G; Taddei GL
Int J Gynecol Cancer; 2006; 16(1):416-22. PubMed ID: 16445668
[TBL] [Abstract][Full Text] [Related]
38. Detection of PIK3CA E545A mutation in circulating tumor DNA of a patient affected by uterine carcinosarcoma.
Fantappiè G; Malentacchi F; Turrini I; Sorbi F; Castiglione F; Vergoni F; Ammatuna C; Antonuzzo L; Fambrini M; Noci I; Pillozzi S
Anticancer Drugs; 2020 Sep; 31(8):880-883. PubMed ID: 32796408
[TBL] [Abstract][Full Text] [Related]
39. The genetic landscape of endometrial clear cell carcinomas.
DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
[TBL] [Abstract][Full Text] [Related]
40. The pan-cancer analysis of the two types of uterine cancer uncovered clinical and prognostic associations with m6A RNA methylation regulators.
Zou Z; Zhou S; Liang G; Tang Z; Li K; Tan S; Zhang X; Zhu X
Mol Omics; 2021 Jun; 17(3):438-453. PubMed ID: 34110327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]